ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
· ars pharmaceuticals, inc.
AI Briefing
- ARS Pharmaceuticals reports its first full year of neffy revenues of $72.2 million.
- The company updates on the commercialization of its neffy epinephrine nasal spray.
- ARS Pharmaceuticals to release its 2025 annual report on February 25, 2025.
Advertisement